Austin, TX, June 21, 2013 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris") announces today that it is presenting at the American Diabetes Association 73nd Scientific Sessions in Chicago, IL from June 21 to 25. Steve Prestrelski, Ph.D. and Chief Executive Officer, will present on Xeris' soluble glucagon formulation based on biocompatible, non-aqueous solutions.
Poster 1: "Diabetes, Comparative Preclinical Safety-Pharmacology Study of Soluble Non-Aqueous Glucagon (G-Pen™) vs. Lilly Glucagon™, for Treatment of Severe Hypoglycemia" (Dr. Jacque Pappo, Steve Prestrelski, Ph.D., and Brett Newswanger) will be presented by Dr. Prestrelski on Sunday, June 23 from 12:00pm to 2:00pm CDT #402-P, Poster Category 02, Complications - Hypoglycemia.
Dr. Prestrelski will also be presenting in the Guided Audio Poster Tour question and answer session "Hypoglycemia-The Barrier" on Monday, June 24 from 1:00pm to 2:00pm CDT.
Poster 2: "Pharmacokinetics and Pharmacodynamics of a Chemically Stable Micro-Dosed Glucagon in a Diabetic Swine Model of Type 1 Diabetes" (Dr. Steve Russell (M.D., Ph.D.), Edward Damiano, Ph.D., Firas El-Khatib, Ph.D., John Jiang, Ph.D., Steve Prestrelski, Ph.D., Patrick Sluss, Ph.D., Katherine McKeon, Brett Newswanger, and Nancy Scott) will also be presented by Dr. Prestrelski on Saturday, June 22, 11:30 am to 1:30 pm CDT #1015-P, Poster Category 01-E, Clinical Therapeutics/New Technology - Non Insulin Injectables.
The presentation abstracts can be accessed through the ADA website, www.diabetes.org at 10am CDT on Saturday, June 22, 2013. Poster 1 will be available on Xeris' website in the "News & Events" section, at www.xerispharma.com at the same time.
About Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Austin, Texas. Xeris develops injectable therapeutics to treat endocrine and metabolic diseases, as well as therapeutics for indications in neurology and immunology. Its low-volume and ready-to-use pharmaceuticals provide convenient and patient-friendly devices through the subcutaneous delivery of concentrated, non-aqueous pastes or liquid drug formulations. Its delivery technologies will eliminate reconstitution of biologics, simplify administration, and ease the pain of injections for millions of patients and caregivers. For more information please visit the Xeris website at: www.xerispharma.com
Source:Xeris Pharmaceuticals, Inc.